Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD PhD, Gilles A. Salles, Kylie D Mason, MBBS, FRACP, FRCPA, PhD, Carla Casulo, MD, Steven Le Gouill, MD PhD, Laurie H Sehn, MD, Hervé Tilly, MD PhD, Guillaume Cartron, MD PhD, Martine ED Chamuleau, MD, Andre Goy, MD, Constantine S. Tam, MD, Pieternella J Lugtenburg, MD PhD, Rebecca Elstrom, MD, Thalia Farazi, MD PhD, Juan Liu, Edith Szafer-Glusman, PhD, Mehrdad Mobasher, MD, Franck Morschhauser

Blood (2016) 128 (22): 3032.

https://doi.org/10.1182/blood.V128.22.3032.3032

Published: 2016

Journal Articles

Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodkgin’s Lymphoma

Marielle J Wondergem, MD, Theresia M Westers, PhD, Otto Visser, MDhD, Josee M Zijlstra, Sonja Zweegman, MD PhD, Martine ED Chamuleau, MD

Blood (2014) 124 (21): 5882.

https://doi.org/10.1182/blood.V124.21.5882.5882

Published: 2014

Journal Articles

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Pier Luigi Zinzani, Bertrand Coiffier, MD PhD, John Radford, Dolores Caballero, Paul Fields, MD PhD, Martine ED Chamuleau, MD, Francesco d'Amore, Corinne Haioun, MD PhD, Catherine Thieblemont, MD PhD, Eva González Barca, MD PhD, Carlos Grande García, MD, Peter W Johnson, MD, Gustaaf W van Imhoff, MD PhD, Andrew Saunders, MD, Karen Dwyer, Franck Morschhauser, MD PhD

Blood (2014) 124 (21): 1763.

https://doi.org/10.1182/blood.V124.21.1763.1763

Published: 2014

Journal Articles

Improved Prognostic Assessment Of Patients With MDS By IPSS-R and MDS-CI

Margot van Spronsen, Margot van Spronsen, Arjan van de Loosdrecht, Martine ED Chamuleau, MD

Blood (2013) 122 (21): 5207.

https://doi.org/10.1182/blood.V122.21.5207.5207

Published: 2013

Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2883.

https://doi.org/10.1182/blood.V122.21.2883.2883

Published: 2013

Journal Articles

R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial,

Michel Van Gelder, Wendim Ghidey, Martine ED Chamuleau, MD, Jan J Cornelissen, MD, PhD, Ka Lung Wu, MD, PhD, Mels Hoogendoorn, S. M. G. J. Daenen, Eefke Petersen, MD, Marinus H. J. van Oers

Blood (2011) 118 (21): 3911.

https://doi.org/10.1182/blood.V118.21.3911.3911

Published: 2011

Journal Articles

Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,

Marielle Wondergem, MD, Josee Zijlstra, Nikie Hoetjes, Martine ED Chamuleau, MD, Sonja Zweegman, MD PhD, Peter C. Huijgens, MD, PhD, Ronald Boellaard, Otto s Hoekstra

Blood (2011) 118 (21): 3658.

https://doi.org/10.1182/blood.V118.21.3658.3658

Published: 2011

Journal Articles

Aberrant Phenotype of blasts in Low and Intermediate-1 Risk Myelodysplastic syndromes Predicts Response of Growth Factor Treatment. a Prospective clinical Phase-II Study.

Maurice JDL van der Vorst, MD, Theresia M Westers, PhD, Martine ED Chamuleau, MD, Corien Eeltink, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2008) 112 (11): 1660.

https://doi.org/10.1182/blood.V112.11.1660.1660

Published: 2008

NARROW

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodkgin’s Lymphoma

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Improved Prognostic Assessment Of Patients With MDS By IPSS-R and MDS-CI

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial,

Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,

Aberrant Phenotype of blasts in Low and Intermediate-1 Risk Myelodysplastic syndromes Predicts Response of Growth Factor Treatment. a Prospective clinical Phase-II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only